Absolute and relative activities of 4' -IODO-4'-deoxydoxorubicin against human colo-rectal tumors, as evaluated by a short-term in vitro assay

R. Villa, N. Zaffaroni, F. C. Giuliani, G. Colella, O. Sanfilippo, R. Silvestrini

Research output: Contribution to journalArticle

Abstract

A short-term antimetabolic assay based on the interference with 3H-thymidine and 3H-uridine incorporation after 3 hours of in vitro treatment and was used to compare the cytotoxicity of a new halogenated anthracycline, 4'-Iodo-4'-deoxydoxorubicin (IDX), with that of its parent compound Doxorubicin (DX) against 44 human colorectal carcinomas. IDX had a marked dose-dependent effect, with frequencies of activity consistently greater than those of DX at all concentrations. The minimal dose of IDX required to induce a significant antimetabolic effect obtained by extrapolation from the dose-effect plots for each drug was 1/10 that of DX (2.3 μg/ml vs 23 μg/ml). When the relative activities of the two drugs on the same tumor specimen were determined, there was 71% to 86% overall agreement, depending on the concentration used. Lack of agreement was always attributed to sensitivity to IDX and resistance to the parent compound.

Original languageEnglish
Pages (from-to)105-108
Number of pages4
JournalAnticancer Research
Volume10
Issue number1
Publication statusPublished - 1990

Keywords

  • 4'-Iodo-4'-deoxydoxorubicin
  • antimetabolic assay
  • colorectal cancer
  • doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Absolute and relative activities of 4' -IODO-4'-deoxydoxorubicin against human colo-rectal tumors, as evaluated by a short-term in vitro assay'. Together they form a unique fingerprint.

  • Cite this